ArticleTranslational andrology and urology2024
Clinicopathologic features and prognosis of incidental prostate cancer after radical cysto-prostatectomy: a comparative study between China and the West.
Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BCa) is one of the most common tumors of the urinary system, imposing a significant societal burden. BCa is categorized into muscle-invasive BCa (MIBC) and non-MIBC (NMIBC) types. Radical cystoprostatectomy (RCP) is the standard treatment for MIBC and refractory NMIBC, but it can lead to serious side effects. Incidental prostate cancer (IPCa) is frequently found in RCP specimens, with varying incidence rates across ethnic groups, ranging from 7.3% to 60%. The clinical significance is unclear, and disparities in incidence and tumor characteristics exist within the Chinese population. The impact of IPCa on survival is debated, highlighting the need for research on its incidence and pathology for tailored interventions. This study aimed to compare the clinicopathological characteristics and prognostic significance of IPCa in RCP specimens taken from Chinese and Western BCa populations. Methods: Data from patients who underwent RCP in our hospital between 2008 and 2022 were collated and compared to data from the Surveillance, Epidemiology, and End Results (SEER) database between 2008 and 2019. Chi-squared and non-parametric testing were conducted with survival analysis to investigate differences between IPCa traits and their impact on prognosis. Results: Twenty-four IPCa cases were detected in 300 patients undergoing RCP, with a median age of 73 [interquartile range (IQR), 67-77] years. The median prostate-specific antigen (PSA) value was 2.81 (IQR, 1.19-4.81) ng/mL. 66.6% (n=16) had Gleason score (GS) ≤6 and all patients were stage T2. There were 315 IPCa patients in the 'Western' sample, with a median age of 68 (IQR, 63-74) years. The median PSA value was 1.9 (IQR, 0.9-4.1) ng/mL. 64.8% (n=204) had GS ≤6 and 93.0% (n=293) were stage T2. Comparative analysis showed that the clinicopathological features of IPCa were similar. Cox's regression analysis showed that T stage [hazard ratio (HR), 1.846; 95% confidence interval (CI): 1.394-2.444; P<0.001] and N stage (HR, 1.416; 95% CI: 1.011-1.984; P=0.04) of BCa were independent risk factors for cancer-specific survival (CSS). Advanced age (HR, 1.043; 95% CI: 1.018-1.069; P=0.001), T stage (HR, 1.569; 95% CI: 1.281-1.922; P<0.001), and N stage (HR, 1.317; 95% CI: 1.012-1.716; P=0.04) were independent risk factors for overall survival (OS). In the subgroup of patients with NMIBC, patients with clinically significant IPCa (csIPCa) had worse OS. Conclusions: There were significant differences in IPCa detection rates between Chinese and Western populations. The main factors affecting survival were patient age and stage of BCa. However, in the NMIBC population, OS for patients with csIPCa appears poorer and further research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.